What does this article add?
CYC is a better option for the first line treatment of ILD in systemic sclerosis , rheumatoid arthritis and primary sjögren syndrome patients compared to AZA treatment. AZA could be an alternative option in inflammatory myositits associated ILD and interstitial pneumonia with autoimmune features with limited disease extent .